Human noroviruses are highly contagious, constantly evolving, incredibly robust in the environment, and linked to debilitating diseases. Symptoms include vomiting and diarrhea, with or without nausea and abdominal cramps. Norovirus infection can be much more severe and widespread in express risk groups, adding infants, children, the elderly and immunocompromised people. In the U. S. alone, noroviruses are to blame for about 21 million cases of acute gastroenteritis per year, adding up to 109,000 hospitalizations, 465,000 emergency room visits and about 900 deaths, according to the CDC. The National Institutes of Health (NIH) estimates the annual burden to the United States at $10. 6 billion. Peak outbreaks occur in semi-gated communities such as nursing homes, hospitals, cruise ships, schools, crisis relief sites, and military surroundings. , there are no approved vaccines or antiviral remedies for norovirus infections.
About CDI-988 CDI-988 was designed and evolved in particular as a broad-spectrum antiviral inhibitor, Cocristal’s proprietary structure-based drug discovery platform technology. They target a highly conserved region at the active site of coronavirus, norovirus and other 3CL viral proteases. Cocristal is authorized to conduct a Phase 1 study of CDI-988 in Australia through the Human Research Ethics Board (HREC) of that country.
About Cocristal Pharma, Inc. Cocristal Pharma, Inc. es a clinical-stage biotechnology company that discovers and develops novel antiviral treatments targeting the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses, and hepatitis C viruses. Cocristal uses unique structure-based technologies and Nobel Prize-winning expertise to create best-in-class antiviral drugs. For more information about Cocristal, visit www. cocristalpharma. com.
Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the initiation and characteristics of a Phase 1 study to CDI-988 as a product. Candidate for dual oral treatment. antiviral treatment opposed to coronavirus-norovirus and the prospective efficacy, clinical benefits and market of this product candidate. The words “believe”, “possibly”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “may also simply”, “target”, “prospective”, “” is likely”, “will”, “expects” and similar expressions, to the extent they apply to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our existing expectations and projections regarding future events. long term. Some or all of the events anticipated by such forward-looking statements may not occur. Important points that could also cause actual effects to differ from those indicated in the forward-looking statements include, but are not limited to, threats related to the economy Australian, delays in production and studies resulting from shortages of hard work and other points, as well as general threats arising from or related to the conduct of a clinical examination of CDI-988, adding the effects of that Examine More data on Our threat points are contained in our filings with the SEC, adding our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Any forward-looking statements we make herein are void. on the date it is carried out. Factors or occasions that may also cause our actual effects to vary may arise from time to time, and it is not imaginable that we are expecting them all. We undertake no legal responsibility to publicly update any forward-looking statements, whether as a result of new data, long-term developments or otherwise, unless required by law.
Media Contact: JQA PartnersJules Abraham917-885-7378Jabraham@jqapartners. com
# # #